drugset / Trial / NCT01527305

A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia

NCT01527305

Phase 4 Completed 212 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of paliperidone palmitate in schizophrenic inpatients who have experienced recent exacerbation of acute schizophrenia (that is within past 4 weeks).

Timeline

Start
2012-06-22
Primary completion
2013-12-31
Completion
2013-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject paliperidone palmitate Unknown 50 mg Intramuscular
Subject paliperidone palmitate Unknown 150 mg Intramuscular

Indications